Mylan’s Matrix Laboratories Ltd. entered an expanded licensing agreement with Gilead Sciences for the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, currently in late-stage development. They include: Elvitegravir, an investigational integrase inhibitor, Cobicistat, an investigational antiretroviral (ARV) boosting agent, and the “Quad,” a once-daily, single-tablet combination of four separate Gilead medicines.

Mylan President Heather Bresch said: “Every patient living with HIV/AIDS has a right to treatment. Matrix has made a significant contribution to dramatically lowering the cost of HIV/AIDS medicines, and we are now focused on expanding access to high-quality treatment to more people who need it. We are pleased to expand our collaboration with Gilead as it will enable more individuals living with HIV/AIDS in resource-limited countries to access the newest innovative medicines.”
   
Under previous licensing agreements Matrix obtained non-exclusive rights to produce and market APIs and finished products, including generic versions of Viread and other TDF-based combinations in 95 developing countries including India. The expanded agreement allows for the sale of Viread, Truvada and other TDF-based combinations in 16 additional countries and for the production and sale of Viread as a treatment for chronic hepatitis B in an expanded territory.